The US Food and Drug Administration’s database3 was mined for topical approvals designed for local action on skin, hair, nails, and mucosal surfaces from January 1, 2000, through December 31, 2014. Using solely publicly available data, this study is exempt from institutional review board approval at Presence Saint Joseph Hospital. Tentative approvals, supplements, and generic approvals were excluded. Transdermal, ocular, intrainhalational, and intranasal products were also excluded. Approvals were classified by the US Food and Drug Administration designation (standard, priority, and orphan) and class (analgesics, anti-infective agents, anti-inflammatories, immunomodulators and chemotherapeutics, retinoids, corticosteroids, and others). The time of approval was determined from the date of the investigational new drug application to the approval date. The primary submitting entity was also determined.